WuXi Biologics seeks spinout, HK listing of bioconjugates-focused joint venture
Another member of the WuXi AppTec family is set to be spun off and separately listed on the Hong Kong Stock Exchange, allowing the contract research, development and manufacturing conglomerate to branch out even further.
The proposed listing would look to raise $500 million, the International Financing Review reports.
WuXi XDC, the subsidiary in question, is a joint venture between WuXi Biologics — the Hong Kong-listed biologics-focused arm — and WuXi STA, which specializes in small molecules and peptides. Formed in June 2021, it offers contract services relating to bioconjugates, including antibody-drug conjugates, peptide conjugates, oligo conjugates and more.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.